Abstracts Archive - Page 650 of 2607 - ACR Meeting Abstracts

Abstract Number: 1422 • ACR Convergence 2022
Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice
Louis Bessette¹, Proton Rahman², John Kelsall³, Jane Purvis⁴, Emmanouil Rampakakis⁵, Allen J. Lehman⁶, Meagan Rachich⁷, Francois Nantel⁸, A. Marilise Marrache⁹ and Odalis Asin-Milan¹⁰, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Memorial University, St. John's, NL, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Peterborough Education, Peterborough, ON, Canada, ⁵McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷Janssen Inc., Guelph, ON, Canada, ⁸Nantel MedSci Consult, Montréal, QC, Canada, ⁹Janssen Inc., Dollard-des-Ormeaux, QC, Canada, ¹⁰Janssen Canada, Laval, QC, Canada
Background/Purpose: Although biologic use in RA has a well-characterized infections risk factor, most studies were done on 1st-generation anti-tumor necrosis factor (TNFi) drugs or post-drug…
Abstract Number: 1409 • ACR Convergence 2022
Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study
Guillermo Guaracha Basañez¹, Irazu Contreras-Yáñez², Vivian Estrada-González², Lexli Pacheco-Santiago², Salvador Valverde-Hernández² and Virginia Pascual Ramos³, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico
Background/Purpose: Patients and physicians can naturally adopt hybrid healthcare models (HC), that combine face-to-face consultations (FFC) with telemedicine. The study's objective was to compare the…
Abstract Number: 1441 • ACR Convergence 2022
Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program
Brendan Denvir¹, Philip Carlucci², Jill Buyon³, H Michael Belmont⁴, Kelly Corbitt¹, Sara Sahl⁵, Jane Salmon⁶, Anca Askanase⁷, Joan Bathon⁷, Laura Geraldino-Pardilla⁸, Yousaf Ali⁹, Ellen M. Ginzler¹⁰, Chaim Putterman¹¹, Caroline Gordon¹², Hilary Parton¹³ and Peter Izmirly³, ¹New York University, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Harbor-University of California Medical Center, Los Angeles, CA, ⁶Hospital for Special Surgery, New York, NY, ⁷Columbia University Medical Center, New York, NY, ⁸Columbia University, New York, NY, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ¹¹Albert Einstein College of Medicine, Bronx, NY, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹³New York City Department of Health and Mental Hygiene, New York, NY
Background/Purpose: Epidemiologic data of secondary connective tissue disease and autoantibody profiles among patients with systemic lupus erythematosus (SLE) remains limited for racial/ethnic populations in the…
Abstract Number: 1442 • ACR Convergence 2022
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Anca Askanase¹, John Conklin², Michelle Petri³, Vasileios Kyttaris⁴, Yevgeniya Gartshteyn⁵, Wei Tang¹, Anja Kammesheidt⁶ and Roberta Alexander², ¹Columbia University Medical Center, New York, NY, ²Exagen, Inc., Vista, CA, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶self, Laguna Beach, CA
Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
Abstract Number: 1439 • ACR Convergence 2022
Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections
Alan Smith¹, Pei-Ling Roerig¹, Jacob Cason², David Fancis², Brian Cooley², Mike Royal³, Vibeke Strand⁴, John Goldman⁵, Roel Querubin⁶ and Russell Ross², ¹4P Therapeutics, Peachtree Corners, GA, ²Sorrento Therapeutics, Atlanta, GA, ³Sorrento Therapeutics, San Diego, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Northside Hospital, Atlanta, GA, ⁶Atlanta Research Center for Rheumatology, Marietta, GA
Background/Purpose: The lymphatic system plays an integral role in the pathology of rheumatoid arthritis (RA)1 and mediates local RA flares2, yet most biologic therapies are…
Abstract Number: 1445 • ACR Convergence 2022
Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India
Pankti Mehta¹, Akansha Srivastava², Amita Aggarwal², Liza Rajasekhar³, Vineetha Shobha⁴, Chengappa Kavadichanda⁵, ASHISH JACOB MATHEW⁶, Parasar Ghosh⁷, Bidyut Das⁸, Avinash Jain⁹, Ranjan Gupta¹⁰ and Manish Rathi¹¹, ¹King George's Medical University, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴St. John’s Medical College Hospital, Bangalore, India, ⁵JIPMER, Pondicherry, Puducherry, India, ⁶Christian Medical College, Vellore, Vellore, India, ⁷Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁸SCB medical college, Cuttack, India, ⁹SMS Medical College, Lucknow, India, ¹⁰All India Institute of Medical Sciences, New Delhi, India, ¹¹PGIMER Chandigarh, Chandigarh, India
Background/Purpose: Gastrointestinal (GI) manifestations of Systemic Lupus Erythematosus (SLE) although rare are often severe. These are difficult to directly attribute to SLE as they can…
Abstract Number: 1447 • ACR Convergence 2022
Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers
Carolina Munoz¹, Michelle Barraclough², Juan Pablo Diaz-Martinez¹, Jiandong Su¹, Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, May Choi⁶, Dennisse Bonilla¹, Simone Appenzeller⁷, Patricia Katz⁸, Dorcas Beaton⁹, Robin Green⁵, Joan Wither¹⁰ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, São Paulo, Brazil, ⁸UCSF, San Rafael, CA, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric lupus(NPSLE), which may occur in the absence of active Systemic Lupus Erythematosus…
Abstract Number: 1446 • ACR Convergence 2022
Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients
Tarek Carlos Salman-Monte¹, Patricia Corzo², Ivan Garcia-Duitama³, ANA Agustí Claramunt³, Irene Carrion Barbera⁴, Salvatore Marsico³ and Jordi Monfort⁵, ¹Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital del Mar, Radiology, Barcelona, Spain, ⁴Hospital del Mar, Rheumatology, Barcelona, Spain, ⁵Hospital del Mar, Barcelona, Spain
Background/Purpose: Joint involvement in SLE is the most frequent manifestation and shows a wide heterogeneity (1) . It has not a valid classification and it…
Abstract Number: 1448 • ACR Convergence 2022
Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
Eldon Jupe¹, Gerald Lushington², Mohan Purushothaman¹, Fabricio Pautasso¹, Georg Armstrong¹, Arif Sorathia¹, Jessica Crawley¹, Vijay Nadipelli³, Bernie Rubin⁴, Ryan Newhardt¹, Melissa Munroe¹ and Brett Adelman¹, ¹Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OR, ³GlaxoSmithKline, Philadelphia, PA, ⁴GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by varied immune dysregulation. SLE patients often experience episodic flares, leading to organ damage…
Abstract Number: 1450 • ACR Convergence 2022
Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis
KONSTANTINOS TSELIOS¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Time to complete remission, subsequent flares and time on immunosuppressives after complete remission are major determinants of the progression to advanced chronic kidney disease…
Abstract Number: 1435 • ACR Convergence 2022
Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study
Kazuhiro Yokota¹, Hayato Nagasawa², Yuji Akiyama³ and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, ²Nagasawa Clinic, Kawagoe, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Efficacy and safety of tocilizumab (TCZ) in the treatment of rheumatoid arthritis (RA) has demonstrated in randomized controlled trials. However, the clinical response to…
Abstract Number: 1413 • ACR Convergence 2022
Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study
Jie Pan¹, Yao-Wei Zou¹, Ying-Ying Zhu², Jian-da Ma³, Jian-Zi Lin³, Tao Wu¹, Ze-Hong Yang², Xue-Pei Zhang¹, Qian Zhang¹, Hu-Wei Zheng¹, Xiao-Ling He⁴, Wan-Mei Cheng⁴ and Lie Dai³, ¹Sun Yat-Sen University, Guangzhou, China, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ³Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ⁴Shanghai Healthare Co. Ltd, Shang hai, China
Background/Purpose: Muscle loss is common in long-standing rheumatoid arthritis (RA) patients. However, less is known about this unfavorable alteration of body composition (BC) and its…
Abstract Number: 1454 • ACR Convergence 2022
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
Sarah Reid¹, Johanna K Sandling¹, Pascal Pucholt¹, Ahmed Sayadi¹, Christopher Sjöwall², Karoline Lerang³, Andreas Jönsen⁴, Anders A Bengtsson⁴, Øyvind Molberg³, Anna Rudin⁵, Solbritt Rantapää-Dahlqvist⁶, Lars Ronnblom⁷ and Dag Leonard¹, ¹Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁶Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁷Uppsala University, Uppsala, Sweden
Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
Abstract Number: 1452 • ACR Convergence 2022
Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis
James Sullivan¹ and Emily Littlejohn², ¹Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Long-term glucocorticoid use can lead to adverse outcomes independent of SLE disease activity. Identifying factors associated with long-term glucocorticoids is an important step towards…
Abstract Number: 1456 • ACR Convergence 2022
Latin-American Systemic Lupus Erythematosus Clusters
Rosana Quintana¹, Romina Nieto², Marina Scolnik³, Nidia Meras⁴, Cintia Otaduy⁵, María Emilia Sattler⁶, Luciana González Lucero⁷, Nicolas Perez⁸, Ana Silva⁹, Odirlei Monticielo¹⁰, Angela Luzia B Duarte¹¹, Edgard Reis Neto¹², Milena Mimica¹³, Gustavo Aroca Martinez¹⁴, Gerardo Quintana-Lopez¹⁵, Mario Moreno Alvarez¹⁶, Miguel Angel Saavedra Salinas¹⁷, Margarita Portela¹⁸, Luis H Silveira¹⁹, Ignacio García Valladares²⁰, Carlos Abud-Mendoza²¹, Jorge Esquivel-Valerio²², Maria Duarte²³, Roberto Muñoz Louis²⁴, Vicente Juárez²⁵, Eduardo Ferreira Borba Neto²⁶, Luis Catoggio²⁷, Graciela Alarcón²⁸, Jose Puerta²⁹, Guillermina Harvey³⁰, Elisa Novati³¹, Valeria Arturi³², Wilfredo Grageda³³, Cecilia Pisoni³⁴, Francinne Machado Riobeiro³⁵, Emily Figueiredo Neves Yuki²⁶, Iris Guerra Herrera³⁶, Gabriel Tobón³⁷, Andres Cadena Bonfanti¹⁴, Hilda Fragoso-Loyo³⁸, Marie Teresa de Martinez³⁹, Claudia Selene Mora Trujillo⁴⁰, Manuel Ugarte-Gil⁴¹, Ernesto Zavala Flores⁴², Ricardo Robaina⁴³, Gonzalo Silveira⁴⁴, Federico Zazzetti⁴⁵, Ashley Orillion⁴⁶, Guillermo Pons-Estel⁴⁷, Bernardo Pons-Estel² and Urbano Sbarigia⁴⁸, ¹Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ²Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Córdoba, Cordoba, Argentina, ⁵Hospital Córdoba, Córdoba, Argentina, ⁶Sanatorio Británico, Paraná, Argentina, ⁷Hospital Padilla, San Miguel de Tucumán, Argentina, ⁸Instituto Lanari, Buenos Aires, Argentina, ⁹Hospital das Clinicas, Univerisad Federal de Goias, Goiania, Brazil, ¹⁰Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹¹Universidade Federal de Pernambuco, Recife, Brazil, ¹²Universidad Federal São Paulo, São Paulo, Brazil, ¹³Universidad San Sebastián, Santiago, Chile, ¹⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ¹⁵Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital. Bogota, Colombia; Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia. Bogota, Colombia; Department of Internal Medicine. School of Medicine, Universidad de Los Andes, Bogotá, Colombia, ¹⁶Hospital Luis Vernaza, Guayaquil, Ecuador, ¹⁷IMSS, Ciudad de México, Mexico, ¹⁸Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ¹⁹Instituto Nacional de Cardiología, Ciudad de México, Mexico, ²⁰CEIBAC, SC, Guadalajara, Mexico, ²¹Hospital Central and Faculty of Medicine, UASLP, San Luis Potosí, Mexico, ²²Hospital Universitario “Dr. José Eleuterio Gonzalez", Monterrey, Mexico, ²³Hospital de Clínicas Paraguay, Asunción, Paraguay, ²⁴Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ²⁵MSP, Salta, Argentina, ²⁶Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ²⁷Hospital Italiano de Buenos Aires, Olivos, Argentina, ²⁸The University of Alabama at Birmingham, Oakland, ²⁹Rheumatology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain, ³⁰Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Santa Fe, Argentina, ³¹Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³²Hospital HIGA San Martín, Buenos Aires, Argentina, ³³Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ³⁴CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ³⁵Hospital Universitario Pedro Ernesto, UERJ, Rio de Janiero, Brazil, ³⁶Hospital del Salvador, Santiago, Chile, ³⁷Fundación Valle del Lili, Calí, Colombia, ³⁸Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³⁹Hospital de Clínicas I, Montevideo, Uruguay, ⁴⁰Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴¹Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁴²Hospital Cayetano Heredia, San Martín de Porres Distric, Peru, ⁴³Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁴Grupo de Investigacion de EAIS y Reumatológicas, A Coruña, Spain, ⁴⁵Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁴⁶Janssen, Horsham, PA, ⁴⁷CREAR, Rosario, Argentina, ⁴⁸Johnson & Johnson, Beerse, Belgium
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. The identification of patient subgroups or clusters may be useful for the management…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].